Eli Lilly and Co. has appointed two new Executive Committee members and has expanded other senior leaders’ roles to support the company in its next wave of growth.

Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer and head of development at Denali Therapeutics, where she built and led the company’s translational medicine and clinical development strategy.

Adrienne Brown, currently group vice president of corporate business development at Lilly, has been promoted to executive vice president and president, Lilly Immunology, and will join the Executive Committee. Throughout her 20 year career at Lilly, Brown has held leadership positions with expanding responsibilities across U.S. and Japan operations, business development, sales, marketing and commercial strategy, including leading the U.S. launch of Mounjaro.

Daniel Skovronsky, M.D., Ph.D., will assume an expanded role as chief scientific and product officer, and president, Lilly Research Laboratories, overseeing R&D as well as global launches and product strategy for Cardiometabolic Health, Immunology and Neuroscience. He will continue to report directly to David A. Ricks, Lilly chair and CEO, and remain on the Executive Committee. New Executive Committee members Ho and Brown and continuing Executive Committee member Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health, will report to Skovronsky.

Jacob Van Naarden, executive vice president and president, Lilly Oncology, will also assume an expanded role with the corporate business development function moving under his leadership. Van Naarden will continue to report directly to Ricks and remain on the Executive Committee.